SCHEMBL29845748

SCHEMBL29845748

Clc1ccc(N2CCCC2)nn1

nearest known ligand 0.96

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.96
BPTF Q12830 1/20 0.69
LMNA P02545 2/20 0.57
HTT P42858 1/20 0.57
CHRNB2 P17787 3/20 0.53
CHRNA4 P43681 3/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 1/20 0.53
CNR2 P34972 2/20 0.51
MEN1 O00255 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
CHRNB4 P30926 2/20 0.49
CHRNA3 P32297 2/20 0.49
CHRM4 P08173 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL421732 1.00 CYP1A2 (0.96) CYP1A2BPTFLMNAHTTCHRNB2
SCHEMBL1849545 0.98 CYP1A2 (1.00) CYP1A2BPTFLMNAHTTCHRNB2
SCHEMBL9990416 0.96 CYP1A2 (0.88) CYP1A2BPTFLMNAHTTCHRNB2
SCHEMBL6360151 0.87 BPTF (0.80) CYP1A2BPTFLMNAHTTCHRNB2
SCHEMBL6354020 0.86 BPTF (0.84) CYP1A2BPTFLMNAHTTCHRNB2
SCHEMBL20929374 0.84 CYP1A2 (0.69) CYP1A2BPTFLMNAHTTKMT2A
SCHEMBL5238778 0.84 BPTF (0.87) CYP1A2BPTFLMNAHTTCHRNB2
SCHEMBL6352737 0.84 CYP1A2 (0.69) CYP1A2BPTFLMNAHTTKMT2A
SCHEMBL14503215 0.84 CYP1A2 (0.75) CYP1A2BPTFLMNAHTTALDH1A1
SCHEMBL1770262 0.83 CYP1A2 (0.69) CYP1A2BPTFLMNAHTTCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115397806-A Aryl and heteroaryl compounds and their therapeutic use in conditions associated with altered activity of galactocerebrosidase 增益治疗股份有限公司 2022-11-25 CN disclosed
EP-4065546-A1 ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE Gain Therapeutics SA (CH) 2022-10-05 EP disclosed